NCT06390319 - Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

December 27, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2033

Conditions

T-cell Acute Lymphoblastic LeukemiaT-cell LymphomaMixed Phenotype Acute Leukemia

Interventions

DRUG

Dexamethasone

Given orally (PO) or intravenously (IV).

DRUG

Vincristine

Given IV.

DRUG

Daunorubicin

Given IV.

DRUG

Calaspargase pegol

Given IV.

DRUG

Dasatinib

Given PO

DRUG

Venetoclax

Given PO (ETP, near-ETP, and MPAL only).

DRUG

Bortezomib

Given IV (T-LLy only).

DRUG

Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)

Given Intrathecal (IT), Age adjusted.

DRUG

Cyclophosphamide

Given IV.

DRUG

Cytarabine

Given IV or IT.

DRUG

Mercaptopurine

Given PO.

DRUG

Nelarabine

Given IV

DRUG

Methotrexate

Given IT, IV, PO or intramuscular (IM).

DRUG

Thioguanine

Given PO (participants intolerant to mercaptopurine).

Trial Locations (3)

38105

RECRUITING

St. Jude Children's Research Hospital, Memphis

74136

RECRUITING

Saint Francis Children's Hospital, Tulsa

92123

RECRUITING

Rady Children's Hospital, San Diego